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Background
Biologic immunotherapy such as anti-TNF or monoclonal
antibody against CD20 protein revolutionized the treat-
ment of autoimmune diseases. Unfortunately, the patients
receiving this therapy are at higher risk for bacterial or
fungal infections, and at risk for reactivation of latent viral
infections and latent tuberculosis. We present a series of
patients receiving biologic therapy, admitted in the Adults
3 Department of the National Institute for Infectious
Diseases “Prof. Dr. Matei Balş” for prolonged fever.
Case report
All of the patients were diagnosed with tuberculosis. One
patient was treated with rituximab for non-Hodgkin lym-
phoma, 2 patients were treated with infliximab for rheu-
matoid arthritis, one patient was treated with infliximab
for ankylosing spondylitis and one patient was treated
with etanercept for severe psoriasis. Two of the patients
were diagnosed with pulmonary tuberculosis and for three
patients the localization of tuberculosis was not identified.
All of the patients had quantiferon TB gold positive. Only
one of the patients had positive microbiologic tests for
tuberculosis. All of the patients had a good therapeutic
response after anti-tuberculous therapy. None of the
patients had been tested for latent tuberculosis prior to
initiation of biologic therapy.
Conclusion
We emphasize the importance of anti-tuberculosis pro-
phylaxis for patients diagnosed with latent tuberculosis,
before the start of biologic therapy. The diagnosis of
latent tuberculosis remains an important issue especially
in a country with high incidence of tuberculosis.
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